- Consolidated Net Sales Increased 27% Sequentially and 7% Year-over-Year to
$64 Million - Net Income of
$7.1 Million or$0.06 Per Share; Operating Cash Flow of$8.9 Million - Company Achieves Record Harvest Yields in Delta Facilities in 1H’26 with Improved Cost of Production
- Record Export Sales of
$20.9 Million Grew 74% YoY and 43% Sequentially - Record Q2 Cannabis Segment Adjusted EBITDA from Continuing Ops of
$15.3 Million or 29% of Sales Netherlands and Canadian Expansion CapEx Nearly Complete; Closes Q2 with$73 Million in Cash
Management Commentary
President and Chief Executive Officer
“We’re having a record year of production in our
“We’re continuing to gain traction with our efforts to grow market share in convenience product categories in
“We’re entering the second half of the year in a position of strength, and we’re positioned for continued profitable growth regardless of our entry point and timing into the U.S. market with a global cannabis enterprise that is now approaching 50% of revenues from growing international markets. Our
“We closed the second quarter with
Second Quarter 2026 Financial Highlights
(All comparable periods are for the second quarter of 2025 unless otherwise stated)
Cannabis Operations
- Net sales increased 5% to
$53.5 million , from$50.8 million in the prior year period; - Gross margin increased to 51% from 42% in the prior year period;
- Net income improved to
$8.6 million from$7.1 million , an increase of 21% year-over-year; - Adjusted EBITDA from continuing operations increased 16% to
$15.3 million or 28.5% of sales, compared to$13.1 million or 25.8% of sales in the prior year period; and - Cash flow from operations was
$8.9 million .
- Maintained the Company’s top five overall market share position in the Canadian market and expanded its market share in vapes and infused pre-rolls, now positioning the Company’s brand portfolio among the top 10 nationally in all major product categories1.
- Achieved record production from the Company’s
Delta, British Columbia facilities during 1H’26. Increased yields and greater operating efficiencies led to lower production costs during Q2, and favorable sales mix helped drive nine percentage points of year-over-year cannabis segment gross margin expansion. - International export sales increased 74% year-over-year and 43% sequentially to a record high of
$20.9 million . The Company believes it remains the largest exporter of medical cannabis toEurope with a leading market share position inGermany . - The Company commenced cultivation at its Phase II facility in Groningen,
Netherlands during Q2. The Groningen facility will bring the Company’s maximum annualized production capacity inthe Netherlands to approximately 10 metric tonnes and is expected to ramp to full production into early 2027. - During Q2 the Company harvested its first crop from the first half of its
Delta 2 greenhouse expansion, and announced that it is accelerating technology upgrades quicker than previously anticipated due to increasing global demand. TheDelta 2 expansion is expected to yield approximately 15 metric tonnes of dried, trimmed flower during the second half of 2026. TheDelta 2 expansion is expected to ramp to its full production capacity of 40 metric tonnes by mid-2027, bringing total production capacity from theDelta campus to approximately 160 metric tonnes of dried, trimmed flower annually.
Corporate and Other
- On
May 27, 2026 the Company was awarded “Producer of the Year” at the 2026 Business of Cannabis Awards inLondon . The award recognizes excellence and innovation in cannabis cultivation practices, techniques, and product quality, and celebrates cultivators who have demonstrated exceptional skill, dedication, and expertise in producing high-quality cannabis while adhering to best practices in sustainability, compliance, and safety. - On
June 5, 2026 the Company entered into securities purchase agreements for the purchase and sale of 7,500,000 common shares of the Company in a registered direct offering subscribed to by twoU.S . institutional investors. The offering yielded gross proceeds of approximately$15 million before deducting placement agent fees and other expenses.
- Based on estimated retail sales from HiFyre, other third parties and provincial boards.
Conference Call
Village Farms’ management team will host a conference call to discuss its second quarter 2026 financial results today,
The live question and answer session will be limited to analysts; however, others are invited to submit questions ahead of the conference call via email at investorrelations@villagefarms.com. Management will address questions received via email during the question-and-answer session as time permits.
About
In
In
Contact Information
Senior Vice President, Corporate Affairs
Phone: (407) 495-5067
Email: sgibbons@villagefarms.com
| Cannabis Performance Summary | ||||||||||
| (thousands except % metrics) | Three Months Ended | |||||||||
| 2026 | 2025 | |||||||||
| USD $ | USD $ | Change | ||||||||
| Total | $ | 53,523 | $ | 50,842 | 5 | % | ||||
| Total Cost of Sales | $ | 26,246 | $ | 29,502 | -11 | % | ||||
| Gross Profit | $ | 27,277 | $ | 21,340 | 28 | % | ||||
| Gross Margin % | 51 | % | 42 | % | 21 | % | ||||
| SG&A | $ | 15,203 | $ | 11,606 | 31 | % | ||||
| Net income | $ | 8,603 | $ | 7,098 | 21 | % | ||||
| Adjusted EBITDA from Continuing Operations (1) | $ | 15,273 | $ | 13,123 | 16 | % | ||||
| Adjusted EBITDA from Continuing Operations Margin (2) | 29 | % | 26 | % | 12 | % | ||||
| Cash flow from Operations | $ | 8,996 | $ | 19,172 | -53 | % | ||||
| (millions except % metrics) | Six Months Ended | |||||||||
| 2026 | 2025 | |||||||||
| USD $ | USD $ | Change | ||||||||
| Total | $ | 103,267 | $ | 90,069 | 15 | % | ||||
| Total Cost of Sales | $ | 54,682 | $ | 53,460 | 2 | % | ||||
| Gross Profit | $ | 48,585 | $ | 36,609 | 33 | % | ||||
| Gross Margin % | 47 | % | 41 | % | 15 | % | ||||
| SG&A | $ | 30,023 | $ | 23,342 | 29 | % | ||||
| Net income | $ | 13,383 | $ | 9,946 | 35 | % | ||||
| Adjusted EBITDA from Continuing Operations (1) | $ | 25,479 | $ | 20,012 | 27 | % | ||||
| Adjusted EBITDA from Continuing Operations Margin (1) | 25 | % | 22 | % | 14 | % | ||||
| Cash flow from Operations | $ | (2,814 | ) | $ | 22,058 | NM | ||||
| (1) | Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect our business performance. Adjusted EBITDA from continuing operations includes the Company’s 86.6% interest in Rose LifeScience. For a reconciliation of Adjusted EBITDA from continuing operations to net income (the most comparable measure under GAAP), see “Reconciliation of Adjusted EBITDA from Continuing Operations to Net Income (Loss)” below. | |
| (2) | Adjusted EBITDA from Continuing Operations Margin is calculated as Adjusted EBITDA from continuing operations (which is a non-GAAP measure) divided by Total |
| Composition of Sales by Channel | ||||||||
| Three Months Ended | ||||||||
| Classification | 2026 | 2025 | ||||||
| Cannabis: | ||||||||
| Canadian Branded (1) | $ | 23,017 | $ | 24,962 | ||||
| Canadian Non-Branded | 3,040 | 7,077 | ||||||
| International Exports | 20,897 | 11,980 | ||||||
| 3,224 | 3,841 | |||||||
| Netherlands Branded | 3,345 | 2,483 | ||||||
| Other | — | 499 | ||||||
| Total Cannabis | 53,523 | 50,842 | ||||||
| Other | ||||||||
| Produce | 10,185 | 8,574 | ||||||
| Clean Energy | 269 | 483 | ||||||
| Total Revenue | $ | 63,977 | $ | 59,899 | ||||
| (1) | Canadian Branded revenues are shown net of excise tax on products. Excise tax on products was |
| Six Months Ended | ||||||||
| Classification | 2026 | 2025 | ||||||
| Cannabis: | ||||||||
| Canadian Branded (1) | $ | 46,865 | $ | 47,713 | ||||
| Canadian Non-Branded | 8,417 | 13,367 | ||||||
| International Exports | 35,478 | 17,368 | ||||||
| 6,357 | 7,745 | |||||||
| Netherlands Branded | 6,008 | 2,969 | ||||||
| Other | 142 | 907 | ||||||
| Total Cannabis | 103,267 | 90,069 | ||||||
| Other | ||||||||
| Produce | 10,293 | 8,601 | ||||||
| Clean Energy | 655 | 909 | ||||||
| Total Revenue | $ | 114,215 | $ | 99,579 | ||||
| (1) | Canadian Branded revenues are shown net of excise tax on products. Excise tax on products was |
Presentation of Financial Results
The Company’s financial statements for the three and six months ended
| RESULTS OF OPERATIONS | |||||||||||||||
| (In thousands of | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Sales | $ | 63,977 | $ | 59,899 | $ | 114,215 | $ | 99,579 | |||||||
| Cost of sales | (34,004 | ) | (37,557 | ) | (63,256 | ) | (63,057 | ) | |||||||
| Gross profit | 29,973 | 22,342 | 50,959 | 36,522 | |||||||||||
| Selling, general and administrative expenses | (18,811 | ) | (15,411 | ) | (34,753 | ) | (30,030 | ) | |||||||
| Interest expense | (477 | ) | (814 | ) | (1,000 | ) | (1,516 | ) | |||||||
| Interest income | 343 | 109 | 951 | 184 | |||||||||||
| Foreign exchange (loss) gain | (597 | ) | 1,792 | (1,145 | ) | 1,708 | |||||||||
| Other (loss) income | 24 | 4,430 | (159 | ) | 4,451 | ||||||||||
| Income (loss) before taxes and equity method investment income | 10,455 | 12,448 | 14,853 | 11,319 | |||||||||||
| Provision for income taxes | (3,262 | ) | (2,503 | ) | (4,930 | ) | (3,486 | ) | |||||||
| Equity method investment income, net of tax | — | — | — | — | |||||||||||
| Income (loss) from continuing operations | 7,193 | 9,945 | 9,923 | 7,833 | |||||||||||
| (Loss) Income from discontinued operations, net of tax | — | 16,294 | — | 11,291 | |||||||||||
| Income (loss) including non-controlling interests | 7,193 | 26,239 | 9,923 | 19,124 | |||||||||||
| Less: net (income) loss attributable to non-controlling interests, net of tax | (48 | ) | 258 | 139 | 670 | ||||||||||
| Net income (loss) attributable to | $ | 7,145 | $ | 26,497 | $ | 10,062 | $ | 19,794 | |||||||
| Adjusted EBITDA from continuing operations (1) | $ | 15,411 | $ | 17,111 | $ | 25,311 | $ | 20,560 | |||||||
| Basic income (loss) per share attributable to | |||||||||||||||
| Continuing operations | $ | 0.06 | $ | 0.09 | $ | 0.09 | $ | 0.08 | |||||||
| Discontinued operations | - | 0.15 | - | 0.10 | |||||||||||
| Basic income (loss) per share attributable to | $ | 0.06 | $ | 0.24 | $ | 0.09 | $ | 0.18 | |||||||
| Diluted income (loss) per share attributable to | |||||||||||||||
| Continuing operations | $ | 0.06 | $ | 0.10 | $ | 0.08 | $ | 0.08 | |||||||
| Discontinued operations | - | 0.14 | - | 0.10 | |||||||||||
| Diluted income (loss) per share attributable to | $ | 0.06 | $ | 0.24 | $ | 0.08 | $ | 0.18 | |||||||
| (1) | Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect our business performance. Adjusted EBITDA from continuing operations includes the Company’s 86.6% interest in Rose LifeScience. For a reconciliation of Adjusted EBITDA from continuing operations to net income (the most comparable measure under GAAP), see “Reconciliation of Adjusted EBITDA from Continuing Operations to Net Income (Loss)” below. |
We caution that our results of operations for the three and six months ended
| SEGMENTED RESULTS OF OPERATIONS | |||||||||||||||
| (In thousands of | |||||||||||||||
| For The Three Months Ended | |||||||||||||||
| Cannabis | Other | Corporate | Total | ||||||||||||
| Sales | $ | 53,523 | $ | 10,454 | $ | — | $ | 63,977 | |||||||
| Cost of sales | (26,246 | ) | (7,758 | ) | — | (34,004 | ) | ||||||||
| Selling, general and administrative expenses | (15,203 | ) | (712 | ) | (2,896 | ) | (18,811 | ) | |||||||
| Other expense, net | (207 | ) | (204 | ) | (296 | ) | (707 | ) | |||||||
| Income (loss) before taxes and equity method investment income | 11,867 | 1,780 | (3,192 | ) | 10,455 | ||||||||||
| Provision for income taxes | (3,216 | ) | (46 | ) | — | (3,262 | ) | ||||||||
| Equity method investment income, net of tax | — | — | — | — | |||||||||||
| Income (loss) including non-controlling interests | 8,651 | 1,734 | (3,192 | ) | 7,193 | ||||||||||
| Less: net loss attributable to non-controlling interests, net of tax | (48 | ) | — | — | (48 | ) | |||||||||
| Net income (loss) | $ | 8,603 | $ | 1,734 | $ | (3,192 | ) | $ | 7,145 | ||||||
| Adjusted EBITDA from Continuing Operations(1) | $ | 15,273 | $ | 2,776 | $ | (2,638 | ) | $ | 15,411 | ||||||
| Basic income (loss) per share | $ | 0.08 | $ | 0.01 | $ | (0.03 | ) | $ | 0.06 | ||||||
| Diluted income (loss) per share | $ | 0.08 | $ | 0.01 | $ | (0.03 | ) | $ | 0.06 | ||||||
| For The Three Months Ended | |||||||||||||||
| Cannabis | Other | Corporate | Total | ||||||||||||
| Sales | $ | 50,842 | $ | 9,057 | $ | — | $ | 59,899 | |||||||
| Cost of sales | (29,502 | ) | (8,055 | ) | — | (37,557 | ) | ||||||||
| Selling, general and administrative expenses | (11,606 | ) | (843 | ) | (2,962 | ) | (15,411 | ) | |||||||
| Other (expense) income, net | (507 | ) | 4,471 | 1,553 | 5,517 | ||||||||||
| Income (loss) before taxes and equity method investment income | 9,227 | 4,630 | (1,409 | ) | 12,448 | ||||||||||
| Provision for income taxes | (2,387 | ) | (135 | ) | 19 | (2,503 | ) | ||||||||
| Equity method investment income, net of tax | — | — | — | — | |||||||||||
| Income (loss) from continuing operations | 6,840 | 4,495 | (1,390 | ) | 9,945 | ||||||||||
| Income from discontinued operations net of tax | — | 16,294 | — | 16,294 | |||||||||||
| Income (loss) including non-controlling interests | 6,840 | 20,789 | (1,390 | ) | 26,239 | ||||||||||
| Less: net loss attributable to non-controlling interests, net of tax | 258 | — | — | 258 | |||||||||||
| Net income (loss) | $ | 7,098 | $ | 20,789 | $ | (1,390 | ) | $ | 26,497 | ||||||
| Adjusted EBITDA from Continuing Operations(1) | $ | 13,123 | $ | 6,833 | $ | (2,845 | ) | $ | 17,111 | ||||||
| Basic income (loss) per share from continuing operations | $ | 0.06 | $ | 0.04 | $ | (0.01 | ) | $ | 0.09 | ||||||
| Basic income per share from discontinued operations | $ | - | $ | 0.15 | $ | - | $ | 0.15 | |||||||
| Basic income (loss) per share | $ | 0.06 | $ | 0.19 | $ | (0.01 | ) | $ | 0.24 | ||||||
| Diluted income (loss) per share from continuing operations | $ | 0.06 | $ | 0.05 | $ | (0.01 | ) | $ | 0.10 | ||||||
| Diluted income per share from discontinued operations | $ | - | $ | 0.14 | $ | - | $ | 0.14 | |||||||
| Diluted income (loss) per share | $ | 0.06 | $ | 0.19 | $ | (0.01 | ) | $ | 0.24 | ||||||
| For The Six Months Ended | |||||||||||||||
| Cannabis | Other | Corporate | Total | ||||||||||||
| Sales | $ | 103,267 | $ | 10,948 | $ | — | $ | 114,215 | |||||||
| Cost of sales | (54,682 | ) | (8,574 | ) | — | (63,256 | ) | ||||||||
| Selling, general and administrative expenses | (30,023 | ) | (1,224 | ) | (3,506 | ) | (34,753 | ) | |||||||
| Other expense, net | (517 | ) | (426 | ) | (410 | ) | (1,353 | ) | |||||||
| Income (loss) before taxes and equity method investment income | 18,045 | 724 | (3,916 | ) | 14,853 | ||||||||||
| Provision for income taxes | (4,801 | ) | (129 | ) | — | (4,930 | ) | ||||||||
| Equity method investment income, net of tax | — | — | — | — | |||||||||||
| Income (loss) from continuing operations | 13,244 | 595 | (3,916 | ) | 9,923 | ||||||||||
| Less: net loss attributable to non-controlling interests, net of tax | 139 | — | — | 139 | |||||||||||
| Net income (loss) | $ | 13,383 | $ | 595 | $ | (3,916 | ) | $ | 10,062 | ||||||
| Adjusted EBITDA from continuing operations (1) | $ | 25,479 | $ | 2,753 | $ | (2,921 | ) | $ | 25,311 | ||||||
| Basic income (loss) per share from continuing operations | $ | 0.12 | $ | - | $ | (0.03 | ) | $ | 0.09 | ||||||
| Basic income per share from discontinued operations | $ | - | $ | - | $ | - | $ | - | |||||||
| Basic income (loss) per share | $ | 0.12 | $ | - | $ | (0.03 | ) | $ | 0.09 | ||||||
| Diluted income (loss) per share from continuing operations | $ | 0.11 | $ | - | $ | (0.03 | ) | $ | 0.08 | ||||||
| Diluted income per share from discontinued operations | $ | - | $ | - | $ | - | $ | - | |||||||
| Diluted income (loss) per share | $ | 0.11 | $ | - | $ | (0.03 | ) | $ | 0.08 | ||||||
| For The Six Months Ended | |||||||||||||||
| Cannabis | Other | Corporate | Total | ||||||||||||
| Sales | $ | 90,069 | $ | 9,510 | $ | — | $ | 99,579 | |||||||
| Cost of sales | (53,460 | ) | (9,597 | ) | — | (63,057 | ) | ||||||||
| Selling, general and administrative expenses | (23,342 | ) | (1,586 | ) | (5,102 | ) | (30,030 | ) | |||||||
| Other expense (income), net | (709 | ) | 3,943 | 1,593 | 4,827 | ||||||||||
| (Loss) income before taxes and equity method investment income | 12,558 | 2,270 | (3,509 | ) | 11,319 | ||||||||||
| Provision for income taxes | (3,282 | ) | (204 | ) | — | (3,486 | ) | ||||||||
| Equity method investment income, net of tax | — | — | — | — | |||||||||||
| Income (loss) from continuing operations | 9,276 | 2,066 | (3,509 | ) | 7,833 | ||||||||||
| Income from discontinued operations net of tax | — | 11,291 | — | 11,291 | |||||||||||
| Income (loss) including non-controlling interests | 9,276 | 13,357 | (3,509 | ) | 19,124 | ||||||||||
| Less: net loss attributable to non-controlling interests, net of tax | 670 | — | — | 670 | |||||||||||
| Net income (loss) | $ | 9,946 | $ | 13,357 | $ | (3,509 | ) | $ | 19,794 | ||||||
| Adjusted EBITDA from continuing operations (1) | $ | 20,012 | $ | 5,404 | $ | (4,856 | ) | $ | 20,560 | ||||||
| Basic (loss) income per share from continuing operations | $ | 0.09 | $ | 0.02 | $ | (0.03 | ) | $ | 0.08 | ||||||
| Basic loss per share from discontinued operations | $ | - | $ | 0.10 | $ | - | $ | 0.10 | |||||||
| Basic (loss) income per share | $ | 0.09 | $ | 0.12 | $ | (0.03 | ) | $ | 0.18 | ||||||
| Diluted (loss) income per share from continuing operations | $ | 0.09 | $ | 0.02 | $ | (0.03 | ) | $ | 0.08 | ||||||
| Diluted loss per share from discontinued operations | $ | - | $ | 0.10 | $ | - | $ | 0.10 | |||||||
| Diluted (loss) income per share | $ | 0.09 | $ | 0.12 | $ | (0.03 | ) | $ | 0.18 | ||||||
| (1) | Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations presented for these segments may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect the underlying business performance of the Company. For a reconciliation of Adjusted EBITDA from continuing operations to net income (the most comparable measure under GAAP), see “Reconciliation of Adjusted EBITDA from Continuing Operations to Net Income (Loss)” below. |
Reconciliation of Adjusted EBITDA from Continuing Operations to Net Income (Loss)
The following tables reflect a reconciliation of Adjusted EBITDA from continuing operations to net income (loss) from continuing operations, as presented by the Company:
| For The Three Months Ended | |||||||||||||||
| (in thousands of | Cannabis | Other | Corporate | Total | |||||||||||
| Net income (loss) from continuing operations | $ | 8,603 | $ | 1,734 | $ | (3,192 | ) | $ | 7,144 | ||||||
| Add: | |||||||||||||||
| Amortization and depreciation | 3,483 | 777 | 19 | 4,279 | |||||||||||
| Foreign currency exchange (gain) loss | (60 | ) | 43 | 406 | 389 | ||||||||||
| Interest expense (income), net | 35 | 207 | (108 | ) | 134 | ||||||||||
| Provision for income taxes | 3,216 | 46 | — | 3,262 | |||||||||||
| Share-based compensation | 56 | — | 237 | 293 | |||||||||||
| Deferred financing fees | 67 | — | — | 67 | |||||||||||
| Loss on disposal of assets | — | (31 | ) | — | (31 | ) | |||||||||
| Adjustments attributable to non-controlling interest | (127 | ) | — | — | (127 | ) | |||||||||
| Adjusted EBITDA from continuing operations (1) | 15,273 | 2,776 | (2,638 | ) | 15,411 | ||||||||||
| For The Three Months Ended | |||||||||||||||
| (in thousands of | Cannabis | Other | Corporate | Total | |||||||||||
| Net income (loss) from continuing operations | $ | 7,098 | $ | 4,495 | $ | (1,390 | ) | $ | 10,203 | ||||||
| Add: | |||||||||||||||
| Amortization and depreciation | 3,117 | 1,913 | 38 | 5,068 | |||||||||||
| Foreign currency exchange gain | (84 | ) | (130 | ) | (1,529 | ) | (1,743 | ) | |||||||
| Interest expense (income), net | 316 | 414 | (25 | ) | 705 | ||||||||||
| Provision for (recovery of) income taxes | 2,387 | 135 | (19 | ) | 2,503 | ||||||||||
| Share-based compensation | 37 | 6 | 80 | 123 | |||||||||||
| Deferred financing fee | 47 | — | — | 47 | |||||||||||
| Other impairments | 217 | — | — | ||||||||||||
| Adjustments attributable to non-controlling interest | (12 | ) | — | — | (12 | ) | |||||||||
| Adjusted EBITDA from continuing operations (1) | 13,123 | 6,833 | (2,845 | ) | 17,111 | ||||||||||
| For The Six Months Ended | |||||||||||||||
| (in thousands of | Cannabis | Other | Corporate | Total | |||||||||||
| Net income (loss) from continuing operations | $ | 13,383 | $ | 595 | $ | (3,916 | ) | $ | 10,062 | ||||||
| Add: | — | — | — | — | |||||||||||
| Amortization and depreciation | 6,985 | 1,554 | 43 | 8,582 | |||||||||||
| Foreign currency exchange loss | 15 | 123 | 799 | 937 | |||||||||||
| Interest expense (income), net | 64 | 383 | (388 | ) | 59 | ||||||||||
| Provision for income taxes | 4,801 | 129 | — | 4,930 | |||||||||||
| Share-based compensation | 128 | — | 541 | 669 | |||||||||||
| Deferred financing fees | 139 | — | — | 139 | |||||||||||
| Loss (gain) on disposal of assets | 118 | (31 | ) | — | 87 | ||||||||||
| Adjustments attributable to non-controlling interest | (154 | ) | — | — | (154 | ) | |||||||||
| Adjusted EBITDA from continuing operations (1) | 25,479 | 2,753 | (2,921 | ) | 25,311 | ||||||||||
| For The Six Months Ended | |||||||||||||||
| (in thousands of | Cannabis | Other | Corporate | Total | |||||||||||
| Net income (loss) from continuing operations | $ | 9,946 | $ | 2,066 | $ | (3,509 | ) | $ | 8,503 | ||||||
| Add: | — | — | — | — | |||||||||||
| Amortization and depreciation | 6,055 | 2,273 | 82 | 8,410 | |||||||||||
| Foreign currency exchange (gain) loss | (135 | ) | (82 | ) | (1,544 | ) | (1,761 | ) | |||||||
| Interest expense (income), net | 457 | 924 | (49 | ) | 1,332 | ||||||||||
| Provision for income taxes | 3,282 | 204 | — | 3,486 | |||||||||||
| Share-based compensation | 85 | 19 | 164 | 268 | |||||||||||
| Other Impairments | 47 | — | — | 47 | |||||||||||
| 217 | — | — | 217 | ||||||||||||
| Adjustments attributable to non-controlling interest | 58 | — | — | 58 | |||||||||||
| Adjusted EBITDA from continuing operations (1) | 20,012 | 5,404 | (4,856 | ) | 20,560 | ||||||||||
| (1) | Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations presented for these segments may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect the underlying business performance of the Company. |
This press release is intended to be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the three and six months ended
Cautionary Statement Regarding Forward-Looking Information
As used in this Press Release, the terms “Village Farms”, “Village Farms International”, the “Company”, “we”, “us”, “our” and similar references refer to
This Press Release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the
The Company has based these forward-looking statements on factors and assumptions about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Although the forward-looking statements contained in this Press Release are based upon assumptions that management believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond the Company's control, which may cause the Company's or the industry's actual results, performance, achievements, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, the factors contained in the Company's filings with securities regulators, including this Press Release and the Company’s most recently filed annual report on Form 10-K and quarterly report on Form 10-Q.
When relying on forward-looking statements to make decisions, the Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking statements made in this Press Release relate only to events or information as of the date on which the statements are made in this Press Release. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
| Condensed Consolidated Statements of Financial Position | ||||||||
| (In thousands of | ||||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 72,931 | $ | 81,189 | ||||
| Restricted cash | — | 5,063 | ||||||
| Trade receivables, net | 32,406 | 23,151 | ||||||
| Inventories, net | 46,669 | 41,519 | ||||||
| Other receivables | 1,397 | 324 | ||||||
| Prepaid expenses and deposits | 6,923 | 3,191 | ||||||
| Total current assets | 160,326 | 154,437 | ||||||
| Non-current assets | ||||||||
| Property, plant and equipment, net | 190,058 | 185,712 | ||||||
| Investments | 6,276 | 6,276 | ||||||
| 42,775 | 44,365 | |||||||
| Intangibles, net | 21,137 | 23,647 | ||||||
| Deferred tax asset | 564 | 694 | ||||||
| Right-of-use assets | 5,388 | 4,066 | ||||||
| Other assets | 1,943 | 3,899 | ||||||
| Total assets | $ | 428,467 | $ | 423,096 | ||||
| LIABILITIES | ||||||||
| Current liabilities | ||||||||
| Trade payables | $ | 17,587 | $ | 15,747 | ||||
| Current maturities of long-term debt | 5,249 | 4,885 | ||||||
| Accrued sales taxes | 7,068 | 8,695 | ||||||
| Accrued liabilities | 16,699 | 13,960 | ||||||
| Lease liabilities - current | 1,169 | 1,198 | ||||||
| Income tax payable | — | 12,151 | ||||||
| Other current liabilities | 2,836 | 1,950 | ||||||
| Total current liabilities | 50,608 | 58,586 | ||||||
| Non-current liabilities | ||||||||
| Long-term debt | 34,713 | 28,769 | ||||||
| Deferred tax liability | 17,329 | 18,494 | ||||||
| Lease liabilities - non-current | 5,058 | 3,855 | ||||||
| Other non-current liabilities | 2,111 | 3,330 | ||||||
| Total liabilities | 109,819 | 113,034 | ||||||
| MEZZANINE EQUITY | ||||||||
| Redeemable non-controlling interest | 6,447 | 10,164 | ||||||
| SHAREHOLDERS’ EQUITY | ||||||||
| Common shares, no par value per share - unlimited shares authorized; 121,844,464 shares issued and outstanding at | 407,031 | 392,380 | ||||||
| Additional paid in capital | 24,931 | 29,374 | ||||||
| Accumulated other comprehensive loss | (17,248 | ) | (9,281 | ) | ||||
| Retained earnings | (102,513 | ) | (112,575 | ) | ||||
| Total shareholders’ equity | 312,201 | 299,898 | ||||||
| Total liabilities, mezzanine equity and shareholders’ equity | $ | 428,467 | $ | 423,096 | ||||
| Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) | ||||||||||||||||
| (In thousands of | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Sales | $ | 63,977 | $ | 59,899 | $ | 114,215 | $ | 99,579 | ||||||||
| Cost of sales | (34,004 | ) | (37,557 | ) | (63,256 | ) | (63,057 | ) | ||||||||
| Gross profit | 29,973 | 22,342 | 50,959 | 36,522 | ||||||||||||
| Selling, general and administrative expenses | (18,811 | ) | (15,411 | ) | (34,753 | ) | (30,030 | ) | ||||||||
| Interest expense | (477 | ) | (814 | ) | (1,000 | ) | (1,516 | ) | ||||||||
| Interest income | 343 | 109 | 951 | 184 | ||||||||||||
| Foreign exchange (loss) gain | (597 | ) | 1,792 | (1,145 | ) | 1,708 | ||||||||||
| Other income (loss) | 24 | 4,430 | (159 | ) | 4,451 | |||||||||||
| Income before taxes and equity method investment income | 10,455 | 12,448 | 14,853 | 11,319 | ||||||||||||
| Provision for income taxes | (3,262 | ) | (2,503 | ) | (4,930 | ) | (3,486 | ) | ||||||||
| Equity method investment income, net of tax | — | — | — | — | ||||||||||||
| Income from continuing operations | 7,193 | 9,945 | 9,923 | 7,833 | ||||||||||||
| Income from discontinued operations, net of tax | — | 16,294 | — | 11,291 | ||||||||||||
| Income including non-controlling interests | 7,193 | 26,239 | 9,923 | 19,124 | ||||||||||||
| Less: net (income) loss attributable to non-controlling interests, net of tax | (48 | ) | 258 | 139 | 670 | |||||||||||
| Net income attributable to | $ | 7,145 | $ | 26,497 | $ | 10,062 | $ | 19,794 | ||||||||
| Basic income per share attributable to | ||||||||||||||||
| Continuing operations | $ | 0.06 | $ | 0.09 | $ | 0.09 | $ | 0.08 | ||||||||
| Discontinued operations | - | 0.15 | - | 0.10 | ||||||||||||
| Basic income per share attributable to | $ | 0.06 | $ | 0.24 | $ | 0.09 | $ | 0.18 | ||||||||
| Diluted income per share attributable to | ||||||||||||||||
| Continuing operations | $ | 0.06 | $ | 0.10 | $ | 0.08 | $ | 0.08 | ||||||||
| Discontinued operations | - | 0.14 | - | 0.10 | ||||||||||||
| Diluted income per share attributable to | $ | 0.06 | $ | 0.24 | $ | 0.08 | $ | 0.18 | ||||||||
| Weighted average number of common shares used in the computation of net income (loss) per share (in thousands): | ||||||||||||||||
| Basic | 116,192 | 112,347 | 115,728 | 112,342 | ||||||||||||
| Diluted | 124,721 | 112,736 | 125,824 | 112,607 | ||||||||||||
| Income including non-controlling interests | $ | 7,193 | $ | 26,239 | $ | 9,923 | $ | 19,124 | ||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation adjustment | (4,665 | ) | 9,870 | (8,196 | ) | 10,835 | ||||||||||
| Comprehensive loss including non-controlling interests | 2,528 | 36,109 | 1,727 | 29,959 | ||||||||||||
| Comprehensive loss (income) attributable to non-controlling interests | 72 | (239 | ) | 418 | 100 | |||||||||||
| Comprehensive income attributable to | $ | 2,600 | $ | 35,870 | $ | 2,145 | $ | 30,059 | ||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (In thousands of | ||||||||
| (Unaudited) | ||||||||
| Six Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Cash flows provided by (used in) operating activities: | ||||||||
| Income from continuing operations including non-controlling interests | $ | 9,923 | $ | 7,833 | ||||
| Adjustments to reconcile net income attributable to | ||||||||
| Depreciation and amortization | 8,582 | 8,410 | ||||||
| Amortization of deferred charges | 139 | 47 | ||||||
| Interest expense | 1,000 | 1,516 | ||||||
| Interest paid on long-term debt | (757 | ) | (1,613 | ) | ||||
| Unrealized foreign exchange loss (gain) | 217 | (87 | ) | |||||
| Loss on disposal of assets | 87 | — | ||||||
| Non-cash lease expense | 491 | 619 | ||||||
| Share-based compensation | 669 | 268 | ||||||
| Deferred income taxes | 200 | (935 | ) | |||||
| Changes in non-cash working capital items | (28,435 | ) | 6,207 | |||||
| Net cash (used in) provided by operating activities from continuing operations | (7,884 | ) | 22,265 | |||||
| Cash flows used in investing activities: | ||||||||
| Purchases of property, plant and equipment | (15,462 | ) | (5,289 | ) | ||||
| Net cash used in investing activities from continuing operations | (15,462 | ) | (5,289 | ) | ||||
| Cash flows provided by (used in) financing activities: | ||||||||
| Proceeds from issuance of common shares | 15,000 | — | ||||||
| Issuance costs | (958 | ) | — | |||||
| Proceeds from borrowings | 8,952 | — | ||||||
| Repayments on borrowings | (2,387 | ) | (4,554 | ) | ||||
| Share repurchases | (6,787 | ) | — | |||||
| Acquisition of redeemable non-controlling interest | (1,280 | ) | ||||||
| Proceeds from exercise of warrants and options | 182 | — | ||||||
| Other financing activities | (182 | ) | (432 | ) | ||||
| Net cash provided by (used in) financing activities from continuing operations | 12,540 | (4,986 | ) | |||||
| Discontinued Operations | ||||||||
| Net cash (used in) provided by operating activities from discontinued operations | — | (6,818 | ) | |||||
| Net cash (used in) provided by investing activities from discontinued operations | — | 38,710 | ||||||
| Net cash (used in) provided by financing activities from discontinued operations | — | (4,000 | ) | |||||
| Net cash flows provided by discontinued operations | — | 27,892 | ||||||
| Effect of exchange rate changes on cash and cash equivalents | (2,515 | ) | 475 | |||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (13,321 | ) | 40,357 | |||||
| Cash, cash equivalents and restricted cash, beginning of period | 86,252 | 24,631 | ||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 72,931 | $ | 64,988 | ||||
Source: